Clinical Trials Browser

Phase 1/2 × Withdrawn × sintilimab × Clear all

NCT05572463 2022-11-18

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Phase 1/2 Withdrawn

Melanoma, Neoplasms